266 results on '"Congly, Stephen"'
Search Results
2. Causes and Outcomes of Medicolegal Proceedings Following Gastrointestinal Endoscopy in Canada
3. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
4. Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, Canada
5. Quality of life, clinical outcomes and cost utilization of endoscopic therapy in patients with Barrett's esophagus and early esophageal cancer—an 8-year Canadian experience.
6. Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients.
7. Quality standards on management of alcohol-related liver disease from the UK—targets and tribulations
8. Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis
9. Spending on nucleos(t)ide analogues for hepatitis B in medicaid beneficiaries: 2012-2021.
10. Medicare Part D Spending for Hepatitis B Virus Drugs: Completing the Picture and Extending the Dataset
11. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis
12. A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B
13. Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites
14. Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers
15. Exception points for liver transplantation: A Canadian review
16. Intermittent Proton Pump Inhibitor Therapy in Low-Risk Non-Variceal Upper Gastrointestinal Bleeding May Be Significantly Cost-Saving
17. The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial
18. Successful Treatment of a Reinfected Liver Graft Because of Receipt of a HCV-Positive Kidney
19. Distinguishing Between Sex and Gender Is Critical for Research in Transplantation
20. Comparing Magnetic Resonance Imaging and Contrast‐Enhanced Ultrasound ( CEUS ) for the Characterization of Nodules Found on Hepatocellular Carcinoma Surveillance
21. Diagnosis of esophageal varices by liver stiffness and serum biomarkers in virus-related compensated advanced chronic liver disease.
22. TRENDS IN MEDICARE VS MEDICAID SPENDING ON CYSTIC FIBROSIS DRUGS: AN ECONOMIC EVALUATION.
23. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA)
24. Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
25. Chronic hepatitis E: an important entity for clinicians to be aware of
26. Factors Associated With Geographic Disparities in Gastrointestinal Cancer Mortality in the United States
27. Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: a retrospective cohort study
28. Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B
29. Tu1261: IMPACT OF THE COVID-19 PANDEMIC ON THE EPIDEMIOLOGY OF ALCOHOL-ASSOCIATED HEPATITIS
30. Is diabetes a risk factor for malignancy post-transplant in liver transplant recipients?
31. An Incidental Finding of Spontaneous Hepatic Artery Thrombosis in a Healthy Patient
32. Tu1109 TRENDS IN MEDICAID SPENDING FOR HEPATITIS C TREATMENT FROM 2012-2021
33. Su1594 EVOLVING PUBLIC INTEREST IN FATTY LIVER DISEASE NOMENCLATURE: ANALYZING GOOGLE SEARCH TRENDS
34. The Worldwide Burden of NAFLD: A Systematic Review and Meta-Analysis of Prevalence and Incidence
35. Extramedullary Myeloma to the Liver Following Bispecific Antigen T-Cell Treatment for Refractory Multiple Myeloma
36. Embolization of Portosystemic Shunts for Treatment of Medically Refractory Hepatic Encephalopathy
37. Portal Vein Thrombosis: Should Anticoagulation Be Used?
38. Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort
39. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B
40. ID: 3524554 IMPROVED QUALITY OF LIFE AFTER ENDOSCOPIC THERAPY FOR BARRETT’S ESOPHAGUS AND EARLY ESOPHAGEAL CANCER
41. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting
42. Fr123 CANADIAN COST UTILIZATION FOR ENDOTHERAPY IN PATIENTS WITH BARRETT'S ESOPHAGUS AND EARLY ESOPHAGEAL CANCER
43. Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996–2016
44. Additional file 2 of The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial
45. Additional file 1 of The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial
46. Additional file 3 of The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial
47. Impact of specialized multidisciplinary care on cirrhosis outcomes and acute care utilization
48. Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres
49. Association of Quantitative HBsAg Titres with Clinical Outcomes and Genotype in Patients with Chronic Hepatitis B (CHB): 910
50. Canadian liver transplant allocation for hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.